Literature DB >> 1723740

Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal.

J D Baumgartner1.   

Abstract

The unknowns persisting in the understanding of the mode of action of anti-core lipopolysaccharide antibodies are discussed, and a study of two anti-lipid A monoclonal antibodies is reviewed. This article also critically analyzes the results of the recent clinical trials with monoclonal antibodies.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1723740

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  12 in total

Review 1.  [Endotoxins. Pathogenetic meaning of sepsis].

Authors:  H Rensing
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

2.  The economic impact of HA-1A (Centoxin) against endotoxin.

Authors:  S L Barriere
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

3.  Gram-negative sepsis: what dilemma?

Authors:  J C Hurley
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

Review 4.  Antiendotoxin monoclonal antibodies. What future now?

Authors:  G M Susla; R B Dew
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

5.  Therapies directed against endotoxin--has the time come?

Authors:  Z M Quezado; W D Hoffman
Journal:  West J Med       Date:  1993-04

6.  Fc gamma receptor-dependent clearance is enhanced following lipopolysaccharide in vivo treatment.

Authors:  M S Palermo; F Alves Rosa; G Fernández Alonso; M A Isturiz
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

7.  Similarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice.

Authors:  S Bailat; D Heumann; D Le Roy; J D Baumgartner; E T Rietschel; M P Glauser; F Di Padova
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

8.  An artificial glycoconjugate containing the bisphosphorylated glucosamine disaccharide backbone of lipid A binds lipid A monoclonal antibodies.

Authors:  L Brade; O Holst; H Brade
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.

Authors:  M A Rogy; L L Moldawer; H S Oldenburg; W A Thompson; W J Montegut; S A Stackpole; A Kumar; M A Palladino; M N Marra; S F Lowry
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

10.  Role of endotoxemia in cardiovascular dysfunction and lethality: virulent and nonvirulent Escherichia coli challenges in a canine model of septic shock.

Authors:  W D Hoffman; R L Danner; Z M Quezado; S M Banks; R J Elin; J M Hosseini; C Natanson
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.